Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000996 · ClinicalTrials.gov registry record · Phase 2
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00000996 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants.
The verdict
NCT00000996, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
To study the natural course of AIDS related Kaposi's sarcoma and to determine the usefulness and safety of weekly administration of small doses of doxorubicin. Doxorubicin is one of the most active of all antitumor agents but at currently used doses toxicity is common. When small doses are administered on a weekly schedule, the toxicity of the drug appears to be reduced.
Interventions
- DRUG Doxorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Est. Completion | 1990-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000996
The ClinicalTrials.gov registry entry for NCT00000996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Doxorubicin hydrochloride is the first listed.
NCT00000996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000996 about?
NCT00000996 is a clinical study titled "A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma". To study the natural course of AIDS related Kaposi's sarcoma and to determine the usefulness and safety of weekly administration of small doses of doxorubicin. Doxorubicin is one of the most active of all antitumor agents but at currently used doses toxicity is common. When small doses are administ...
What is the current status of trial NCT00000996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. Estimated completion is 1990-06.
What interventions are being tested in trial NCT00000996?
The interventions under investigation include: Doxorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00000996?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.